Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.
Minoxidil and finasteride are being considered for hair loss due to seborrheic dermatitis and male pattern baldness. The user is also using ketoconazole and zinc pyrithione shampoo.
The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.
The conversation is about finding 1.5mm cartridges for a Dr. Pen device, with a preference for purchasing through Amazon. The discussion does not mention specific hair loss treatments like Minoxidil, finasteride, or RU58841.
The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.
Significant hair improvement was achieved using 3mg Minoxidil and 1.2mg Finasteride over six months, with no side effects, leading to reconsideration of a hair transplant. A detailed skincare routine, including tretinoin and SPF, also improved skin appearance.
A user underwent a 3750 graft hair transplant in Turkey, initially promised 4500 grafts, and is satisfied with the results despite some concerns about donor site size and crown coverage. The user has been on medications like finasteride and minoxidil for about four months and may consider a second transplant in the future.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
KY19382 is discussed as a potential treatment for creating new hair follicles and possibly curing hair loss. The conversation seeks user experiences and sourcing information for KY19382.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.
PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.
The user experienced side effects with both oral and topical finasteride and is considering making their own hair loss treatment using CB-03-01 (Breezula) mixed with minoxidil due to fewer reported side effects. They plan to use a lower concentration than what was used in trials.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.